A gut hormone released after eating that enhances insulin secretion in a glucose-dependent manner. GLP-1 and GIP are the two main incretins. Incretin-based peptide therapies (semaglutide, tirzepatide) exploit this pathway for diabetes and weight management.
"Incretin" is filed under Pharmacology in the PeptideAtlas glossary, alongside 29 other terms in that group.
2 other glossary entries refer to this term in their own definition, which is usually the fastest way to see how it is used in practice.
An incretin hormone that stimulates insulin secretion, inhibits glucagon release, slows gastric emptying, and reduces appetite. GLP-1 receptor agonists like semaglutide mimic this hormone.
An incretin hormone that, like GLP-1, stimulates insulin secretion. Tirzepatide is a dual GLP-1/GIP agonist, and retatrutide is a triple GLP-1/GIP/glucagon agonist.
The proportion of a substance that enters the circulation when introduced into the body and is able to have an active effect. Different administration routes affect bioavailability.
The time required for the concentration of a substance in the body to decrease by half. Determines dosing frequency and accumulation patterns.
Terms that reference this one: GLP-1 (Glucagon-Like Peptide-1), GIP (Glucose-Dependent Insulinotropic Polypeptide).
More Pharmacology terms: Bioavailability, Half-Life, Pharmacokinetics, Pharmacodynamics, First-Pass Metabolism, Receptor Agonist, Receptor Antagonist, Desensitization, Tachyphylaxis, Downregulation, GLP-1 (Glucagon-Like Peptide-1), GIP (Glucose-Dependent Insulinotropic Polypeptide), Glucagon, Amylin, Ghrelin, Growth Hormone Secretagogue (GHS), GHRP (Growth Hormone Releasing Peptide), GHRH (Growth Hormone Releasing Hormone), GHS-R1a (Growth Hormone Secretagogue Receptor), Secretagogue.